5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 189.83▲ | 189.77▲ | 189.86▲ | 186.02▲ | 187.70▲ |
MA10 | 189.84▲ | 189.99▼ | 188.07▲ | 185.57▲ | 187.50▲ |
MA20 | 189.76▲ | 187.66▲ | 186.56▲ | 187.60▲ | 192.43▼ |
MA50 | 189.96▼ | 186.65▲ | 185.91▲ | 186.41▲ | 188.77▲ |
MA100 | 188.17▲ | 185.82▲ | 187.60▲ | 192.93▼ | 174.39▲ |
MA200 | 186.55▲ | 187.78▲ | 186.85▲ | 188.32▲ | 158.83▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.002▼ | 0.183▲ | 0.523▲ | -0.052▼ | -0.619▼ |
RSI | 54.362▲ | 63.922▲ | 64.980▲ | 55.858▲ | 51.391▲ |
STOCH | 43.550 | 61.185 | 79.218 | 38.059 | 55.826 |
WILL %R | -31.373 | -25.608 | -18.154▲ | -30.354 | -46.399 |
CCI | 43.494 | 42.833 | 80.578 | 40.765 | 31.327 |
Tuesday, July 01, 2025 03:38 AM
AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous counterparts.
|
Monday, June 30, 2025 01:30 PM
AbbVie Inc. closed 15.11% below its 52-week high of $218.66, which the company achieved on March 10th.
|
Monday, June 30, 2025 09:16 AM
For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments. Capstan is backed by investors including Pfizer Ventures, Novartis Venture Fund, Eli Lilly and ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/07/25 | 185.01 | 191.76 | 184.39 | 189.99 | 5,937,100 |
30/06/25 | 182.43 | 186.25 | 181.75 | 185.62 | 6,482,600 |
27/06/25 | 187.90 | 188.00 | 181.73 | 182.31 | 29,263,100 |
26/06/25 | 186.53 | 188.99 | 185.79 | 186.79 | 5,729,000 |
25/06/25 | 185.30 | 187.09 | 184.64 | 185.39 | 4,470,000 |
24/06/25 | 184.52 | 186.14 | 183.19 | 185.55 | 4,074,400 |
23/06/25 | 184.49 | 185.80 | 182.30 | 183.76 | 5,157,100 |
20/06/25 | 186.09 | 187.10 | 184.16 | 185.30 | 12,149,400 |
18/06/25 | 185.25 | 187.12 | 183.70 | 185.49 | 2,757,801 |
17/06/25 | 189.16 | 190.61 | 185.055 | 185.48 | 3,477,858 |
|
|
||||
|
|
||||
|
|